Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 ­ Lead program TG4050 to deliver data in 2024. ­ Advancements in other clinical pr...
Source: pharmiweb.com